Ginkgo Bioworks
- 🦄Became a unicorn2017
- 📈Peak valuation$15 Billion ’21
- 💔Became a Unitard2023
- 💸Last valuation~$649M
How it happened
Ginkgo Bioworks pitched itself as a 'cell programming' platform — an organism foundry engineering microbes for industry — and went public in September 2021 via a Soaring Eagle SPAC merger at a ~$15B implied valuation. Revenue stayed small against its enormous valuation and losses, a short-seller attacked its accounting, and the stock collapsed; by 2024 Ginkgo ran a 1-for-40 reverse split to stay listed, its market value down ~96% to about $0.6B. Glassdoor reviews from the slide describe a recurring pattern: brilliant scientists and an inspiring mission undercut by young, inexperienced leadership that kept pivoting strategy, and they recount the 2024 restructuring that cut a quarter of staff, trimmed benefits, and left survivors stretched thin.
Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.
Source: SEC / Macrotrends / GenomeWeb (~$15B implied valuation via Soaring Eagle SPAC Sept 2021, $17.5B announced; ATH $596.80 Nov 2021; 1-for-40 reverse split Aug 2024; ~$581M market cap June 2026)
